Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos

–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exos

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology c

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) w

Capricor sued Nippon Shinyaku over Deramiocel distribution terms, citing pricing issues and patient

Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell an

Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screeni

Here's a look at this week's earnings reports that are most likely to be watched by retail i

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys appro

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidanc

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biote

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines